公司展望

台灣活力生技新藥股份有限公司的創立是基於黃昭蓮博士與徐嘉澤博士共同開發之原創技術平台「模版重複聚合酶連鎖反應」 (linear array epitope technology; LAE technology)，可大幅提升免疫原之抗原性，促進低抗原性標的產生免疫反應，使疫苗得以成功開發。本公司的發展策略是應用LAE technology於生技製藥產業，結合國內外學有專精的生技醫藥界及學界人士共同努力，以建立國際化的創新生技新藥公司為目標，從事生物製劑及抗體開發，預期應用於各種疾病檢驗、治療及預防。

公司的經營方針先期著重開發、生產及銷售疾病診斷試劑；健全財務、活化金流，同時進行生物製劑/疫苗 (抗體藥及衍生治療型疫苗) 之開發及臨床試驗，最終申請到藥證。公司並將積極尋找國際大藥廠策略聯盟，加速國際化與擴展營運規模，為捍衛人類健康福祉而努力。

Company Vision

Taivital Biopharmaceutical Co., LTD. was established using the novel technology platform "Linear array epitope (LAE) technology", developed by Dr. Jaulang Hwang and Dr. Chiatse Hsu for the development of therapeutic vaccine for disease treatment and prevention, and antibody for in vitro clinical diagnosis. This novel LAE technology significantly improves the antigenicity of immunogen, enabling the successful development of many low antigenic immunogen to become useful biologics.   The company's mission is to apply LAE technology in the biopharmaceutical industry, and working closely with both domestic and foreign professionals in the biotech medicine and academic community, looking forward to becoming a world-class innovative biopharmaceutical company, engaged in therapeutic vaccine and IVD antibody development.

The company's business policy is first and foremost of all the development, production, and sale of in vitro diagnostic antibodies.; First once there is cash flow in to maintain and improve the financial stability of the company, and then gradually support the follow-up development of biologics (antibody drugs and therapeutical vaccines) for clinical trials and finally to obtain drug license. The company will continue to actively seek the international strategic alliance of well-established pharmaceutical companies and to accelerate internationalization and expansion of the scale of its operations. Our goal is to safeguard health and human well-being.